deaths (OS)

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
pembrolizumab (10mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-39%